Amarin's Vascepa given marketing exclusivity, shares +4.8% AH

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

The FDA has given Amarin (AMRN) three years of marketing exclusivity for its Vascepa triglyceride-reduction drug.

Though exclusivity officially only extends through July 25, 2015, Amarin expects it to be "supplemented by a 30-month stay under the Hatch-Waxman Amendments that would be triggered after patent infringement litigation initiated by Amarin" in response to the approval of a generic version of Vascepa.

Amarin says it's "evaluating whether to challenge" the FDA's decision to give only three years of exclusivity, rather than five, and insists its efforts to bolster Vascepa's patent position have lowered the relative value of marketing exclusivity.

More on Amarin/Vascepa